share_log

United Therapeutics | 8-K: United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

United Therapeutics | 8-K: United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

美國聯合醫療 | 8-K：聯合療法公司公佈2024年第三季度財務業績
美股SEC公告 ·  2024/10/30 18:37

Moomoo AI 已提取核心訊息

United Therapeutics reported robust Q3 2024 financial results with total revenues increasing 23% YoY to $748.9 million, driven by a 33% growth in Tyvaso product line to $433.8 million. Net income rose 16% to $309.1 million, with earnings per diluted share of $6.39. The company achieved record revenue for the sixth consecutive quarter, marking a $3 billion annual revenue run rate.Tyvaso DPI led the growth with $274.6 million in sales, up 34% YoY, while nebulized Tyvaso contributed $159.2 million, up 32%. Orenitram and Unituxin also showed strong performance with 23% and 19% growth respectively. The growth was primarily attributed to increased patient utilization and strategic price adjustments.The company anticipates multiple clinical milestones in 2025, including data readouts from TETON studies in idiopathic pulmonary fibrosis, ADVANCE OUTCOMES in pulmonary arterial hypertension, and the miroliverELAP phase 1 study. Additionally, United Therapeutics plans to file an investigational new drug application for its UKidney human clinical program.
United Therapeutics reported robust Q3 2024 financial results with total revenues increasing 23% YoY to $748.9 million, driven by a 33% growth in Tyvaso product line to $433.8 million. Net income rose 16% to $309.1 million, with earnings per diluted share of $6.39. The company achieved record revenue for the sixth consecutive quarter, marking a $3 billion annual revenue run rate.Tyvaso DPI led the growth with $274.6 million in sales, up 34% YoY, while nebulized Tyvaso contributed $159.2 million, up 32%. Orenitram and Unituxin also showed strong performance with 23% and 19% growth respectively. The growth was primarily attributed to increased patient utilization and strategic price adjustments.The company anticipates multiple clinical milestones in 2025, including data readouts from TETON studies in idiopathic pulmonary fibrosis, ADVANCE OUTCOMES in pulmonary arterial hypertension, and the miroliverELAP phase 1 study. Additionally, United Therapeutics plans to file an investigational new drug application for its UKidney human clinical program.
美國聯合醫療發佈了2024年第三季度強勁的財務業績，總營業收入同比增長23%，達到74890萬美元，主要受益於Tyvaso產品線增長33%，達到43380萬美元。凈利潤增長16%，達到30910萬美元，每股攤薄收益爲6.39美元。該公司連續第六個季度實現創紀錄的營業收入，年營業收入運行率達到30億美元。Tyvaso DPI以27460萬美元的銷售額引領增長，同比增長34%；而霧化Tyvaso貢獻了15920萬美元，同比增長32%。Orenitram和Unituxin也表現強勁，分別增長23%和19%。這一增長主要歸因於患者利用率的增加和戰略性價格調整。該公司預計在2025年會有多個臨牀里程碑，包括特發性肺纖維化的TETON研究數據公佈、肺動脈高壓的ADVANCE OUTCOMES和miroliverELAP第1期研究。此外，美國聯合醫療計劃爲其UKidney人類臨牀項目提交一項研究新藥申請。
美國聯合醫療發佈了2024年第三季度強勁的財務業績，總營業收入同比增長23%，達到74890萬美元，主要受益於Tyvaso產品線增長33%，達到43380萬美元。凈利潤增長16%，達到30910萬美元，每股攤薄收益爲6.39美元。該公司連續第六個季度實現創紀錄的營業收入，年營業收入運行率達到30億美元。Tyvaso DPI以27460萬美元的銷售額引領增長，同比增長34%；而霧化Tyvaso貢獻了15920萬美元，同比增長32%。Orenitram和Unituxin也表現強勁，分別增長23%和19%。這一增長主要歸因於患者利用率的增加和戰略性價格調整。該公司預計在2025年會有多個臨牀里程碑，包括特發性肺纖維化的TETON研究數據公佈、肺動脈高壓的ADVANCE OUTCOMES和miroliverELAP第1期研究。此外，美國聯合醫療計劃爲其UKidney人類臨牀項目提交一項研究新藥申請。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！